Demystifying Recursion Pharmaceuticals: Insights From 4 Analyst Reviews


Across the recent three months, 4 analysts have shared their insights on Recursion Pharmaceuticals RXRX, expressing a variety of opinions spanning from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 1 0 0 0
Last 30D 1 0 0 0 0
1M Ago 0 0 0 0 0
2M Ago 1 0 0 0 0
3M Ago 1 1 0 0 0

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $16.75, along with a high estimate of $17.00 and a low estimate of $16.00. This upward trend is apparent, with the current average reflecting a 11.67% increase from the previous average price target of $15.00.

Deciphering Analyst Ratings: An In-Depth Analysis

The standing of Recursion Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Gil Blum Needham Maintains Buy $17.00 -
Gil Blum Needham Maintains Buy $17.00 -
Scott Schoenhaus Keybanc Raises Overweight $16.00 $15.00
Gil Blum Needham Raises Buy $17.00 $15.00

Key Insights:

  • Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Recursion Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.
  • Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Recursion Pharmaceuticals compared to the broader market.
  • Price Targets: Gaining insights, analysts provide estimates for the future value of Recursion Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.

To gain a panoramic view of Recursion Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Recursion Pharmaceuticals analyst ratings.

Unveiling the Story Behind Recursion Pharmaceuticals

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Financial Insights: Recursion Pharmaceuticals

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Decline in Revenue: Over the 3 months period, Recursion Pharmaceuticals faced challenges, resulting in a decline of approximately -22.32% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -875.34%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Recursion Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -20.63% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Recursion Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -14.48%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Recursion Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.

Analyst Ratings: Simplified

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!